Apple Watch Users Hope for Return of Blood Oxygen Sensor

Apple’s recent announcement of the Apple Watch Series 10 and Ultra 2 on September 9 came with an unexpected omission: the much-anticipated blood oxygen sensing feature. This capability has been a staple in Apple Watches since the Series 6 launched in 2020, excluding the SE models. However, the feature has been absent in the U.S. for nearly a year, attributed to an ongoing patent dispute with Masimo, a prominent medical device manufacturer. Fortunately, a new report suggests that this crucial feature may soon be reinstated.

According to Bloomberg’s Mark Gurman, the resignation of Masimo’s long-time CEO, Joe Kiani, may pave the way for negotiations between Apple and Masimo. Kiani, known for his vocal criticism of Apple, has left the company, potentially creating an opportunity for both parties to resolve their differences. Gurman speculates that this shift in leadership could facilitate discussions that might lead to a licensing agreement or a settlement that allows Apple to restore the blood oxygen sensing feature in its new Apple Watches.

The return of the blood oxygen sensing feature would undoubtedly be welcomed by consumers. For instance, those who purchased the Apple Watch Ultra 2 at its launch in September 2023 were initially able to utilize this health measurement tool. However, if users desired the new Ultra 2 in its sleek black version, they had to forgo the blood oxygen monitoring feature, as it has been disabled across all Apple Watch models equipped with the sensor since January due to the legal conflict. It is noteworthy that the restriction applies only to Watches sold in the U.S.; the blood oxygen sensor remains functional in Series 10 models purchased outside the country, such as those from the U.K.

While the departure of a key executive does not guarantee a resolution, it does suggest a possibility for the two companies to reassess their positions. Gurman emphasizes that while Apple is unlikely to pursue a formal licensing agreement, there could be room for a mutually beneficial arrangement that allows both companies to drop their litigation. The technical capabilities for blood oxygen monitoring remain intact in the hardware of the new Watches, including the Series 9 and Ultra 2, which were sold after the feature was disabled.

The reintroduction of the blood oxygen sensing capability would not only enhance the functionality of the Apple Watch but could also lead to a collaboration between Apple and Masimo to integrate the latter’s advanced hospital equipment with Apple’s Health app. This collaboration could potentially open new avenues for health monitoring, further solidifying Apple’s position in the health technology space.

As the situation unfolds, consumers eagerly await the outcome of these developments. The blood oxygen sensing feature has proven invaluable for many users, allowing them to monitor their health metrics conveniently from their wrists. For those who prioritize health and wellness in their tech choices, the ability to access this feature once again could influence their decision to upgrade to the latest models.

Apple’s foray into health technology has been a significant part of its product strategy, with the Apple Watch often being touted as a device that empowers users to take control of their health. The potential restoration of the blood oxygen sensing feature aligns with this vision and reflects Apple’s commitment to innovation in the health tech sector. Furthermore, integrating Masimo’s hospital-grade equipment with the Health app could enhance the user experience, providing deeper insights into users’ health and well-being.

In conclusion, the recent resignation of Masimo’s CEO could signal a pivotal moment for Apple in its pursuit of reinstating the blood oxygen sensing feature in its latest watch models. As negotiations between the two companies unfold, consumers remain hopeful for a positive outcome that would not only restore a critical health feature but also open the door for future collaborations that could revolutionize health monitoring technology. Apple’s continuous efforts to enhance its products and prioritize user health underscore its status as a leader in the tech industry, and the potential revival of the blood oxygen sensor could further solidify this reputation. As the tech landscape evolves, both Apple and Masimo will need to navigate this complex situation carefully to meet consumer expectations and advance their respective missions in health technology.